KEGG   DRUG: Enfortumab vedotinHelp
Entry
D11525                      Drug                                   

Name
Enfortumab vedotin (USAN);
Enfortumab vedotin (genetical recombination) (JAN);
Enfortumab vedotin-ejfv;
Padcev (TN)
Product
Formula
C6642H10284N1742O2063S46
Exact mass
148930.0517
Mol weight
149022.148
Remark
Product: D11525<US>
Efficacy
Antineoplastic, Nectin-4 antibody, Tubulin polymerization inhibitor
  Disease
Urothelial cancer [DS:H00022]
Comment
Antibody-drug conjugate
Treatment of cancers expressing Nectin-4
Target
PVRL4 (NECTIN4) [HSA:81607] [KO:K06593]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa04145  Phagosome
hsa04520  Adherens junction
hsa04540  Gap junction
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Other
    PVRL4 (NECTIN4)
     D11525  Enfortumab vedotin (USAN) <US>
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D11525  Enfortumab vedotin (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11525
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11525
BRITE hierarchy
Other DBs
CAS: 1346452-25-2
PubChem: 384585501
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system